title: Vasoactive peptides upregulate mRNA expression and secretion of vascular endothelial growth factor in human airway smooth muscle cells.
abstract: Airway remodeling and associated angiogenesis are documented features of asthma, of which the molecular mechanisms are not fully understood. Angiotensin (ANG)II and endothelin (ET)-1 are potent vasoconstricting circulatory hormones implicated in asthma. We investigated the effects of ANG II and ET-1 on human airway smooth muscle (ASM) cells proliferation and growth and examined the mRNA expression and release of the angiogenic peptide, vascular endothelial growth factor (VEGF). Serum deprived (48 h) human ASM cells were incubated with ANG II (100 nM) or ET-1 (10 nM) for 30 min, 1, 2, 4, 8, 16, and 24 h and the endogenous synthesis of VEGF was examined in relation to control cells receiving serum free culture medium. ET-1 induced time dependent DNA biosynthesis as determined by [3H]-thymidine incorporation assay. Using northern blot hybridization, we detected two mRNA species of 3.9 and 1.7 kb encoding VEGF in the cultured smooth muscle cells. Both ANG II and ET-1 induced the mRNA expression (two- to threefold) and secretion (1.8- to 2.8-fold) of VEGF reaching maximal levels between 4-8 h of incubation. Induced expression and release of VEGF declined after 8 h of ANG II incubation while levels remained elevated in the case of ET-1. The conditioned medium derived from ET-1-treated ASM cells induced [3H]-thymidine incorporation and cell number in porcine pulmonary artery endothelial as well as human umbilical vein endothelial cells. Moreover, the VEGF tyrosine kinase receptor inhibitor blocked the conditioned medium induced mitogenesis in endothelial cells. Our results suggest a potential role for ANG II and ET-1 in ASM cell growth and upregulation of VEGF that may participate in endothelial cell proliferation via paracrine mechanisms and thus causing pathological angiogenesis and vascular remodelling seen during asthma.
authors.affiliation: Department of Pharmacology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands.
authors.forename: Vijay K T
authors.initials: VK
authors.lastname: Alagappan
authors.forename: Anna
authors.initials: A
authors.lastname: Willems-Widyastuti
authors.forename: Ann L B
authors.initials: AL
authors.lastname: Seynhaeve
authors.forename: Ingrid M
authors.initials: IM
authors.lastname: Garrelds
authors.forename: Timo L M
authors.initials: TL
authors.lastname: ten Hagen
authors.forename: Pramod R
authors.initials: PR
authors.lastname: Saxena
authors.forename: Hari S
authors.initials: HS
authors.lastname: Sharma
mesh_terms: D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D001249:Asthma / Q000473:pathology; D049109:Cell Proliferation; D017077:Culture Media, Conditioned / Q000494:pharmacology; D019332:Endothelin-1 / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology; D005786:Gene Expression Regulation; D006801:Humans; D032389:Myocytes, Smooth Muscle / Q000166:cytology*; D009389:Neovascularization, Pathologic; D010455:Peptides / Q000494:pharmacology*; D013552:Swine; D014132:Trachea / Q000166:cytology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism* / Q000502:physiology
chemical_list: D017077:Culture Media, Conditioned; D019332:Endothelin-1; D010455:Peptides; D042461:Vascular Endothelial Growth Factor A; D000804:Angiotensin II